BridgeBio’s Attruby sales expand as a one-time milestone boosts quarterly revenue
BridgeBio ($BBIO) reported third-quarter 2026 revenue of $353.2 million, compared with $120.7 million a year earlier. US Attruby sales reached $253.2 million, increasing approximately $31 million sequentially and $145 million year over year. License and services revenue included a one-time $75 million payment triggered by partner Bayer ($BAYN)’s Beyonttra sales, while royalty revenue reached $20.5 million. The operating loss narrowed to $11.6 million, although the loss attributable to common sha
0